×
Clene EBIT Margin 2018-2025 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Clene ebit margin from 2018 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
View More
Clene EBIT Margin 2018-2025 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Clene ebit margin from 2018 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.3B
Amgen (AMGN)
$153.3B
Gilead Sciences (GILD)
$137.2B
Vertex Pharmaceuticals (VRTX)
$96.3B
Bristol Myers Squibb (BMY)
$92.3B
CSL (CSLLY)
$83.7B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$60.4B
Alnylam Pharmaceuticals (ALNY)
$57B
Argenex SE (ARGX)
$41.1B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$20.8B
Insmed (INSM)
$20.7B
Biogen (BIIB)
$18.7B
Incyte (INCY)
$15.3B
Illumina (ILMN)
$14.7B
Genmab (GMAB)
$14.6B
Genmab (GNMSF)
$14.3B
Ascendis Pharma (ASND)
$11.6B
BioMarin Pharmaceutical (BMRN)
$11.4B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Moderna (MRNA)
$10.4B
Exelixis (EXEL)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Exact Sciences (EXAS)
$8.2B
Bio-Techne Corp (TECH)
$7.9B
Roivant Sciences (ROIV)
$7.9B
Halozyme Therapeutics (HALO)
$7.7B